The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2024 | Biomarker-guided treatment of CLL in the chemo-free era
Valter Gattei, MD, University of Eastern Piedmont, Vercelli, Italy, discusses the most relevant biomarkers for testing in the chemo-free era of chronic lymphocytic leukemia (CLL) treatment. He emphasizes the importance of testing for TP53, immunoglobulin, and BTK mutations, among others, to guide treatment decisions. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
